Xspray Pharma (XSPRAY.ST) Stock Analysis & AI Equity Report
Xspray Pharma (XSPRAY.ST) overview
Xspray Pharma (XSPRAY.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Xspray Pharma reported revenue of SEK 0m and operating profit of SEK -162m; the year-end share price was 31.45 SEK and market capitalisation was SEK 1,209m. Xspray Pharma is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Xspray Pharma's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Xspray Pharma
Xspray Pharma AB (publ) is a Swedish pharmaceutical company developing improved versions of marketed protein kinase inhibitors for cancer treatment. Using its patented HyNap technology, it advances product candidates such as dasatinib, nilotinib, axitinib and cabozantinib through clinical development and regulatory approval, with the aim of improving drug properties and commercial applicability.
Generate the Xspray Pharma report
Xspray Pharma is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Xspray Pharma and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.